A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Trial Profile

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms CheckMate153
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.
    • 16 Feb 2017 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2022.
    • 10 Feb 2017 Planned End Date changed from 1 Jan 2023 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top